Children’s Hospital of Philadelphia

Neuroblastoma remains a devastating clinical problem and continues to be a leading cause of childhood cancer morbidity and mortality despite dramatic increases in therapy. Recent developments in cancer research are changing our understanding of neuroblastoma biology and treatment on the basis of the molecular underpinnings of individual tumors, and are challenging us to design more rational and less toxic therapies.

CHOP Infrastructure Grant

General Pediatric Cancer

Modeling Juvenile Myelomonocytic Leukemia with Patient-Derived Induced Pluripotent Stem Cells

Juvenile Myelomonocytic Leukemia (JMML)

The Tumor Suppressive Role of LNK (SH2B3) in Acute Lymphoblastic Leukemia

Leukemia, Lymphoma

Background

Acute lymphoblastic leukemia (ALL) is the leading cause of cancer-related death in young people, and commonly has a poor outcome in adults. The high-risk ALL is a subtype of ALL that fare a high rate of relapse and mortality. Intriguingly, high-risk ALLs show increased signaling response to growth factors that results in uncontrolled cell proliferation.

Trk-Targeted Therapy of Human Neuroblastomas

Neuroblastoma

Hospital Volume and Induction Mortality in Children, Adolescents, and Young Adults with Acute Leukemia

Leukemia

2016: Jennifer Wilkes is now employed at Seattle Children's Hospital and Regional Medical Center

Alex's Lemonade Stand Foundation for Childhood Cancer

Childhood Cancer Research